Sanofi Acquires Vigil Neuroscience for Neurodegenerative Disease Treatments

570 Million Dollar Deal Sanofi to Acquire Biotechnology Company Vigil Neuroscience

2025-05-26 Source: Sanofi 1 min Reading Time

Related Vendors

Sanofi

Italvacuum, Srl

TRM Filter d.o.o.

Frewitt fabrique de machines SA

Expanding its focus on neurodegenerative diseases, Sanofi plans to acquire Vigil Neuroscience in a deal worth up to 570 million dollars. The move brings VG-3927, a potential Alzheimer’s treatment, into Sanofi’s early-stage pipeline and builds on an earlier strategic investment.

Sanofi will acquire all outstanding shares of Vigil for $8 per share in cash, valuing the company at approximately 470 million dollars.(Bild: frei lizenziert / Pixabay) — Sanofi will acquire all outstanding shares of Vigil for $8 per share in cash, valuing the company at approximately 470 million dollars.
(Bild: frei lizenziert / Pixabay)

French pharmaceutical company Sanofi announced that it has entered into an agreement to acquire Vigil Neuroscience, a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition in neurology, one of Sanofi’s four strategic disease areas, enhances its early-stage pipeline and includes VG-3927, which will be evaluated in a phase 2 clinical study in Alzheimer’s disease.

In June 2024, Sanofi made a 40 million dollar strategic investment in Vigil that included the exclusive right of first negotiation for an exclusive license, grant, or transfer of rights to research, develop, manufacture, and commercialize VG-3927. VGL101, Vigil’s second molecule program, is not included in the transaction.

Sanofi will acquire all outstanding shares of Vigil for 8 dollars per share in cash, valuing the company at approximately 470 million dollars. Additionally, Vigil shareholders will receive a non-transferable contingent value right (CVR) for an extra 2 dollars per share, payable upon the first commercial sale of VG-3927. Key stakeholders, including Bruce Booth, Atlas Ventures, and CEO Ivana Magovčević-Liebisch, representing about 16.2 % of Vigil’s shares, have agreed to support the deal.

The companies expect the transaction to close in Q3 2025.

(ID:50433790)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.